• Work with us
  • External Contractors
Fondazione Toscana Life Sciences
  • IT
  • EN
Toscana Life Sciences
  • THE FOUNDATION
    • Organization
    • History
    • Membership
    • The Legislative Decree No. 231/2001
  • Activity
  • Cluster
  • ITS VITA
  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies
  • Services
    • Business development services
    • Research services
    • Incubation services
    • Protection of intellectual property
  • Projects
    • ERC Advanced Grant OMVac
    • Monoclonal Antibody Discovery (MAD) LAB
    • ERC Advanced Grant VACCIBIOME
    • My First AIRC grant @Tumour Immunology Unit
    • Regions4PerMed
    • COSME-AI4DIAG
    • IDF SHARID
    • BORNTOGEtTHERe
    • SINO-EU‐PERMED
    • Orphan diseases
  • Disseminating
    • TLS Open Doors
    • Scientists for a day
    • Science + Economy = Business
    • Researcher’s Night
    • European Biotech Week
  • TLS4Covid19
  • Stories
Enter any keyword and press enter

ERC Advanced Grant VACCIBIOME

  • Projects
    • ERC Advanced Grant OMVac
    • Monoclonal Antibody Discovery (MAD) LAB
    • ERC Advanced Grant VACCIBIOME
    • My First AIRC grant @Tumour Immunology Unit
    • Regions4PerMed
    • COSME-AI4DIAG
    • IDF SHARID
    • BORNTOGEtTHERe
    • SINO-EU‐PERMED

ERC Advanced Grant – “Cancer Vaccines and Gut Microbiome: an Integrated Approach to Optimize Cancer Immunotherapy”


General description
The project aims at investigating the role of gut microbiome in determining the efficacy of cancer vaccines. The research project, awarded to Prof. Guido Grandi, University of Trento, has a term of five years and benefits from 2,5 million Euros of funding. TLS hosts some labs and scientists and contributes to the development of novel cancer vaccines and the analysis of immune responses in different animal models.


Research activities
The project intends to shed light on the interplay between cancer immunity and gut microbiome as a way to optimize personalized cancer vaccines and immunotherapy. The project originates from two milestone discoveries. First, to be effective cancer immunotherapies have to target CD4+/CD8+ T cell neo-epitopes, which originate from tumour mutations. Second, the gut microbiome influences the effectiveness of anti-PD-1/PD-L1 antibody immunotherapy both in animal models and in humans. We also recently showed in a mouse model that oral gavages with Bifidobacterial cocktails improved the therapeutic power of neo-epitope-based cancer vaccines. How microbiome affects anti-cancer immunity has not been fully elucidated yet and a deep understanding of the underlying mechanisms has the potential to substantially improved cancer immunotherapy. The ultimate goals are: 1) to provide new criteria for neo-epitope selection in personalized cancer vaccines, 2) to develop prognostic tools based on microbiome analysis, and 3) to define microbial species to be used as immune-potentiators in patients undergoing cancer therapy.

Contacts:

Cristina Tinti
c.tinti@toscanalifesciences.org



Principal Investigator: Prof. Guido Grandi

Team at University of Trento, CIBIO
Nicola Segata, prof.
Michele, Tomasi, PhD
Ilaria Zanella, PhD
Others TBD

Team at TLS
Alberto Grandi, PhD
Laura Fantappie’, PhD
Others TBD



Fondazione Toscana Life Sciences
Via Fiorentina, 1
53100 Siena – ITALIA

  • tel +39 0577 231211
  • fax +39 0577 43444
  • info@toscanalifesciences.org; info@pec.fondazionetls.org

Twitter Feeds

Europa chiama Cina per vincere insieme una nuova sfida di salute internazionale. In campo anche la Fondazione Tosca…

@FondazioneTLS 4 Days Ago

🔎Oggi, mercoledì 7 aprile, si celebra la Giornata mondiale della salute. L'OMS lancia l'appello sulla necessità di…

@FondazioneTLS 5 Days Ago

Il viaggio di @Radio1Rai all'interno di Tls prosegue in compagnia della Dottoressa Claudia Sala, responsabile del…

@FondazioneTLS 6 Days Ago

Contatti

    Concedo il consenso al trattamento dei dati personali secondo la nostra Privacy Policy per poter essere contattato da Fondazione Toscana Life Sciences.

©2015-2021 - Fondazione Toscana Life Sciences - P.I. 01194710529 - Codice SDI: SUBM70N - Privacy - Cookie Policy